New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Genmab A/S Sponsored ADR (GMAB) vs Royalty Pharma PLC (RPRX)
- Genmab A/S Sponsored ADR GMAB 50.63 −1.40%
- Royalty Pharma PLC RPRX 68.45 +1.08%
Genmab A/S Sponsored ADR and Royalty Pharma PLC are both Biotechnology companies. Royalty Pharma PLC is the larger, with a market value of $38.9B against $31.5B — 1.2× the size. Genmab A/S Sponsored ADR trades at the lower P/E: 43.0× against 47.2×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 19.8% against 11.4%. Royalty Pharma PLC has the higher net margin (25.7% vs 17.0%) and the lower return on invested capital (5.24% vs 6.89%). Across the 21 metrics below, Genmab A/S Sponsored ADR leads on 13 and Royalty Pharma PLC on 8.
Valuation
Profitability
| Metric | GMAB | RPRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 92.60% | 100.00% | 70.18% |
| Operating margin | 24.30% | 57.14% | 0.00% |
| Net margin | 16.97% | 25.70% | 0.00% |
| Free cash flow margin | (148.32%) | 38.81% | 0.00% |
| Return on equity | 12.07% | 6.93% | (51.58%) |
| Return on assets | 7.31% | 3.47% | (45.91%) |
| Return on invested capital | 6.89% | 5.24% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack